IMMP trades 849.3% below Wall Street's consensus target of $4.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IMMP achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, Immutep Limited (IMMP) has a Wall Street consensus price target of $4.25, based on estimates from 3 covering analysts. With the stock currently trading at $0.45, this represents a potential upside of +849.3%. The company has a market capitalization of $66M.
Analyst price targets range from a low of $3.50 to a high of $5.00, representing a 35% spread in expectations. The median target of $4.25 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, IMMP trades at a trailing P/E of -1.5x. Analysts expect EPS to grow +42.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NKTXNkarta, Inc. | $242M | $3.38 | $9.00 | +166.3% | Buy | — | 12 |
AGENAgenus Inc. | $146M | $3.50 | $7.33 | +109.4% | Buy | 4.5x | 11 |
IMVTImmunovant, Inc. | $8.2B | $40.09 | $45.00 | +12.2% | Buy | — | 23 |
RCUSArcus Biosciences, Inc. | $3.0B | $30.25 | $31.00 | +2.5% | Buy | — | 18 |
TPVGTriplePoint Venture Growth BDC Corp. | $193M | $4.75 | $8.95 | +88.4% | Hold | 5.1x | 12 |
FHTXFoghorn Therapeutics Inc. | $352M | $6.00 | $12.00 | +100.0% | Buy | — | 9 |
BMYBristol-Myers Squibb Company | $118.4B | $57.97 | $62.60 | +8.0% | Hold | 9.2x | 41 |
MRKMerck & Co., Inc. | $318.3B | $128.86 | $133.77 | +3.8% | Buy | 25.1x | 37 |
REGNRegeneron Pharmaceuticals, Inc. | $70.3B | $676.23 | $836.00 | +23.6% | Buy | 14.6x | 48 |
EXELExelixis, Inc. | $14.5B | $57.08 | $50.00 | -12.4% | Hold | 16.2x | 33 |
Quick answers to the most common questions about buying IMMP stock.
The consensus Wall Street price target for IMMP is $4.25, representing 849.3% upside from the current price of $0.4477. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
IMMP has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $4.25 implies 849.3% upside from current levels.
IMMP's current price is $0.4477 with a consensus target of $4.25 (849.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for IMMP, while the most conservative target is $3.5. The consensus of $4.25 represents the median expectation. These targets typically reflect 12-month expectations.
IMMP is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IMMP stock forecast based on 3 Wall Street analysts shows a consensus price target of $4.25, with estimates ranging from $3.5 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on IMMP, with a "Buy" consensus rating and $4.25 price target (849.3% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IMMP analyst price targets range from $3.5 to $5, a 35% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.25 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.